Alzheimer’s disease (AD) imposes a substantial clinical and societal burden, yet currently approved symptomatic therapies do ...
New lecanemab findings highlight the safety and potential benefits of subcutaneous administration for initiation dosing, the potential for additional long-term clinical benefits with continued ...
CAMBRIDGE, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, ...
New lecanemab findings highlight the safety and potential benefits of subcutaneous administration for initiation dosing, the potential for additional long-term clinical benefits with continued ...
Evercore 8th Annual Healthcare Conference December 2, 2025 12:55 PM ESTCompany ParticipantsAlisha Alaimo - President & Head of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback